Key facts
- This page summarizes Jonathan Young's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 14 Mar 2023, 16:19.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Tax liability
No transaction description listed
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
Represents shares required to be sold to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units.
Footnote F2
These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.